Virchows Archiv

, Volume 426, Issue 2, pp 127–134 | Cite as

Trabecular bone structure in patients with primary hyperparathyroidism

  • Martin Vogel
  • Michael Hahn
  • Günter Delling
Original Articles

Abstract

To evaluate the effects of increased parathyroid hormone (PTH)-secretion on trabecular bone structure in patients with primary hyperparathyroidism (PHPT) we have analysed iliac crest biopsies from 84 patients (38 male, 46 female, age 20–85 years) with surgically proven PHPT by using quantitative histomorphometry. As there might be an influence of age or sex, subjects were divided into 4 subgroups according to age (younger than 50 years, older than 50 years) and sex. Eighty four age and sex matched autopsy cases of accidental death served as controls. When compared with age matched controls, trabecular bone volume (BV/TV) and trabecular diameter in PHPT were increased. Trabecular density in PHPT was elevated significantly in the older age-groups. These results suggest a preservation of intertrabecular connectivity, which we were able to confirm by measurement of the number of intertrabecular nodes and trabecular bone pattern factor (TBPf). No differences were demonstrated between male and female subjects. Furthermore, no variations according to the histological type (with or without endosteal fibrosis) could be demonstrated in our material. We conclude that increased trabecular bone volume in PHPT is the result not only of thicker trabecula but also of a reduction of the age-dependent loss of complete trabecular plates due to perforations. Thus PHPT leads to a substantial preservation of intertrabecular connectivity.

Key words

Trabecular bone structure Primary hyperparathyroidism Bone histomorphometry 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Alam AS, Moonga BS, Bevis PJ, Huang CL, Zaidi M (1993) Amylin inhibits bone resorption by a direct effect on the motility of rat osteoclasts. Exp Physiol 78:183–196Google Scholar
  2. 2.
    Azria M, Behhar C, Cooper S (1993) Lack of effect of ipriflavone on osteoclast motility and bone resorption in in vitro and ex vivo studies. Calcif Tissue Int 52:16–20Google Scholar
  3. 3.
    Bergenfelz A, Lindergard B, Ahren B (1992) Biochemical variables associated with bone density in patients with primary hyperparathyroidism. Eur J Surg 158:473–476Google Scholar
  4. 4.
    Burkhardt R (1966) Präparative Voraussetzungen zur Klinischen Histologie des menschlichen Knochenmarks. Blut 14:30–45Google Scholar
  5. 5.
    Chan YL, Furlong TJ, Cornish CJ, Posen S (1985) Dialysis osteodystrophy. A study involving 94 patients. Medicine 64:296–309Google Scholar
  6. 6.
    Charhon SA, Edouard EC, Arlot ME, Meunier PJ (1982) Effects of parathyroid hormone on remodeling of iliac trabecular bone packets in patients with primary hyperparathyroidism. Clin Orthop 162:255–263Google Scholar
  7. 7.
    Christiansen P, Steiniche T, Vesterby A, Mosekilde L, Hessov I, Melsen F (1992) Primary hyperparathyroidism: iliac crest bone volume, structure, remodelling, and balance evaluated by histomorphometric methods. Bone 13:41–49Google Scholar
  8. 8.
    Compston JE, Mellish RW, Garrahan NJ (1987) Age-related changes in iliac crest trabecular microanatomic bone structure in man. Bone 8:289–292Google Scholar
  9. 9.
    Delling G (1975) Endocrine bone diseases. Veröffentlichungen aus der Pathologie. Büngeler W, Eder M, Lennert K, Peters G, Sandritter W, Seifert G (eds) Gustav Fischer Verlag, Stuttgart. 109 ppGoogle Scholar
  10. 10.
    Delling G (1987) Bone morphology in primary hyperparathyroidism — a qualitative and quantitative study of 391 cases. Appl Pathol 5:147–159Google Scholar
  11. 11.
    Delling G, Ziegler R, Schulz A (1975) Bone cells and structure of cancellous bone in primary hyperparathyroidism. A histomorphometric and electron microscopic study. Calcif Tis Res 21:278–283Google Scholar
  12. 12.
    Eriksen EF, Mosekilde L, Melson F (1986) Trabecular bone remodelling and balance in primary hyperparathyroidism. Bone 7:13–221Google Scholar
  13. 13.
    Genant HK, Baron JM, Paloyan E, Jowsey J (1975) Osteosclerosis in primary hyperparathyroidism. Am J Med 59:104–113Google Scholar
  14. 14.
    Hahn M, Vogel M, Pompesius Kempa M, Delling G (1992) Trabecular Bone Pattern Factor — A New Parameter for Simple Quantification of Bone Microarchitecture. Bone 13:327–330Google Scholar
  15. 15.
    Heaney RP (1975) Skeletal remodeling physiology and its relation to metabolic bone disease. NY State J Med 75:1656–1661Google Scholar
  16. 16.
    Hesch RD, Busch U, Prokop M, Delling G, Rittinghaus EF (1989) Increase of vertebral density by combination therapy with pulsatile 1–38 5 and sequential addition of calcitonin nasal spray in arteoporotic patients. Calcif Tis Int 44:176–180Google Scholar
  17. 17.
    Kleerekoper M, Goldstein SA, Feldkamp LA, Flynn MJ, Dickie D, Parfitt AM (1987) Cancellous bone architecture and bone strength. In: Osteoporosis 1987. C. Christiansen, J.S. Johansen, B.J. Riis (eds). Osteopress ApS, Copenhagen, Denmark, pp. 294–300Google Scholar
  18. 18.
    Kragstrup J (1985) Osteons in trabecular bone. Laegeforeningens Forlag, Copenhagen, Denmark, pp 1–15Google Scholar
  19. 19.
    Lloyd HM (1968) Primary hyperparathyroidism: analysis of the role of the parathyroid tumor. Medicine 47:53–71, 1968Google Scholar
  20. 20.
    Minisola S, Rosso R, Romagnoli E, Pacitti MT, Scarnecchia L, Carnevale V, Mazzuoli G (1993) Trabecular bone mineral density in primary hyperparathyroidism: relationship to clinical presentation and biomarkers of skeletal turnoverGoogle Scholar
  21. 21.
    Mosekilde L, Mosekilde M (1988) Iliac crest trabecular bone compressive strength and ash weight is increased in moderate primary hyperparathyroidism (abstract). In: Proceedings of the 5th International Congress on Bone Morphometry. H. Takahashi (ed). Niigata, Japan, 1988, A 111Google Scholar
  22. 22.
    Neer RM, Slovik D, Doppelt S, Daly M, Rosenthal D, Lo C, Potts J (1987) In: Osteoporosis 1987. Christiansen C., Johansen J.S., Riis B.J. (eds). Osteopress ApS, Copenhagen, Denmark, 1987, pp. 829–835Google Scholar
  23. 23.
    Parfitt AM (1976) The actions of parathyroid hormone on bone: relation to bone re-modelling and turnover, calcium homeostasis, and metabolic bone disease. Part III Metabolism 25:1033–1069Google Scholar
  24. 24.
    Parfitt AM, Matthews CHE, Villanueva AR, Kleerekoper M, Frame B, Rao DS (1983) Relationship between surface, volume, and thickness of iliac trabecular bone in aging and in osteoporosis. J Clin Invest 72:1396–1409Google Scholar
  25. 25.
    Parisien M, Silverberg SJ, Shane E, De la Cruz L, Lindsay R, Bilezikian P, Dempster DW (1990) The histomorphometry of bone in primary hyperparathyroidism: preservation of cancellous bone structure. J Clin Endocrinol Metab 70:930–938Google Scholar
  26. 26.
    Parisien M, Mellish RW, Silverberg SJ, Shane E, Lindsay R, Bilezikian JP, Dempster DW (1992) Maintenance of cancellous bone connectivity in primary hyperparathyroidism: trabecular strut analysis. J Bone Miner Res 7:913–919Google Scholar
  27. 27.
    Parsons JA, Bernat M, Bijvoet OL, Meunier PJ, Neer RM, Potts J, Reeve J, Renier JC, Vismans J (1979) Low doses of synthetic fragment of human parathyroid hormone (hPTH 1–34) as a stimulus to bone formation. In: Osteoporosis II, U.S. Barzel (ed), Grune and Stratton, New York, pp. 151–159Google Scholar
  28. 28.
    Pfeilschifter J, Siegrist E, Wuster C, Blind E, Ziegler R (1992) Serum levels of intact parathyroid hormone and alkaline phosphatase correlate with cortical and trabecular bone loss in primary hyperparathyroidism. Acta Endocrinol Copenh 127:319–323Google Scholar
  29. 29.
    Piraino B, Chen T, Cooperstein L, Serge G, Puschett J (1988) Fractures and vertebral bone mineral density in patients with renal osteodystrophy. Clin Nephrol 30:57–62Google Scholar
  30. 30.
    Pozzi-Mucelli RS, Kanton A, Genant HK, Cann CE, Ettinger B, Kolb FO (1983) Quantitative bone mineral analysis in primary hyperparathyroidism (abstract). J Comput Assist Tomogr 7:555Google Scholar
  31. 31.
    Reeve J, Meunier PJ, Parsons JA, Bernat M, Bijvoet OLM, Courpron P, Edouard C, Klenerman L, Neer RM, Renier JC, Slovik D, Vismans FJFE, Potts J (1980) Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial. B M J 280:1340–1344Google Scholar
  32. 32.
    Reeve J, Arlot M, Bernat M, Charon S, Edouard C, Slovik D, Vismans J, Meunier PJ (1981) Calcium 47 kinetic measurements of bone turnover compared to bone histomorphometry in osteoporosis: the influence of human parathyroid hormone fragment (hPTH 1–34) therapy. Metab Bone Dis Rel Res 3:23–30Google Scholar
  33. 33.
    Reeve J, Podbesek RD, Price TR, Arlot M, Bartlett C, Deacon AC, Edouard C, Gren JR, Hesp R, Katz D, Tellez M, Zanelli GD, Zanelli JM, Meunier PJ (1984) Studies of a “short-cycle” ADFR regime using parathyroid peptide hPTH 1–34 in idiopathic osteoporosis and in dog model. In: Osteoporosis II; Christiansen C., Arnaud C.D., Nordin B.E.C., Parfitt A.M., Peck W.A., Riggs B.L. (eds). Aalborg Stiftsbogtrykkeri, Copenhagen, Denmark, pp. 567–573Google Scholar
  34. 34.
    Reeve J, Zanelli JM (1986) Parathyroid hormone and bone. Clin Sci 71:231–238Google Scholar
  35. 35.
    Recklinghausen Fv (1891) Die fibröse oder deformierende Ostitis, die Osteomalacie und die osteoplastische Carinose in ihren gegenseitigen Beziehungen. Festschrift Rudolf Virchow zu seinem 71. Geburtstag; Georg Reimer, Berlin, pp. 1–89Google Scholar
  36. 36.
    Rittinghaus E, Busch U, Prokop M, Delling G, Hesch RD (1987) Increase of vertebral density in osteoporotic patients: combination-therapy with 1–38 hPTH and cyclic addition of calcitonin nasal spray. In: Osteoporosis 1987. Christiansen C., Johansen J.S., Riis B.J. (eds). Osteopress ApS, Copenhagen, Denmark, pp. 888–891Google Scholar
  37. 37.
    Saphier PW, Stamp TCB, Kelsey CR, and Loveridge N (1987) PTH bioactivity in osteoporosis. Bone Min 3:75–83Google Scholar
  38. 38.
    Schenk RK, Olah AJ, Merz WA (1973) Bone cell counts. In: Clinical aspects of metabolic bone disease. Frame B., Parfitt A.M., Duncan H. (eds) Excerpta Medica, Amsterdam, Netherlands, pp. 103–113Google Scholar
  39. 39.
    Slovik DM, Rosenthal DI, Doppelt SH, Daly MA, Murray JA, Neer RM (1985) Reversal of idiopathic osteoporosis by treatment with hPTH (1-34) and 1,25 (OH)2D3. Clin Res 33:444 A (Abstr.)Google Scholar
  40. 40.
    Tam CS, Bayley A, Cross EG, Murray TM, Harrison JE (1982) Increased bone apposition rate in primary hyperparathyroidism: measurements based on short interval labeling of bone. Metabolism 31:759–765Google Scholar
  41. 41.
    Zaidi M, Alam AS, Shankar VS, Bax BE, Moonga BS, Bevis PJ, Pazianas M, Huang CL (1992) A quantitative description of components of in vitro morphometric change in the rat osteoclast model: relationships with cellular function. Eur Biophys J 21:349–355Google Scholar

Copyright information

© Springer-Verlag 1995

Authors and Affiliations

  • Martin Vogel
    • 1
  • Michael Hahn
    • 1
  • Günter Delling
    • 1
  1. 1.Department of Bone Pathology, Institute of PathologyUniversity of HamburgHamburgGermany

Personalised recommendations